Tag Archives: William Tanner

Cantor Fitzgerald Thinks Evofem Biosciences Inc’s Stock is Going to Recover

Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Evofem Biosciences Inc (EVFM – Research Report) yesterday and set a price target of $9. The company’s shares closed yesterday at $3.37, close to its 52-week low of $1.79. Tanner

Cantor Fitzgerald Reiterates a Buy Rating on Arena Pharma (ARNA)

Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Arena Pharma (ARNA – Research Report) yesterday and set a price target of $65. The company’s shares closed yesterday at $38.67. Tanner observed: “: We reiterate our Overweight rating and

Cantor Fitzgerald Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

In a report released yesterday, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price target of $201. The company’s shares closed yesterday at $164.41. Tanner commented: “: We reiterate our

Xencor Inc (XNCR) Receives a Buy from Cantor Fitzgerald

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Xencor Inc (XNCR – Research Report), with a price target of $40. The company’s shares closed yesterday at $37.75. Tanner wrote: “: We reiterate our

Cantor Fitzgerald Reiterates a Hold Rating on Alkermes (ALKS)

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Hold rating on Alkermes (ALKS – Research Report), with a price target of $47. The company’s shares opened today at $37.68, close to its 52-week low of $36.67.

Cantor Fitzgerald Remains a Hold on Amag Pharmaceuticals (AMAG)

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $18. The company’s shares opened today at $18.64. Tanner wrote: “: We reiterate the Neutral rating